RVMD Latest Press Releases

-- October 27, 2026 --

Revolution Medicines to Participate in November 2026 Investor Conferences Globe Newswire 4:05 PM

-- October 23, 2026 --

Revolution Medicines Presents Overall Survival Data for RASONQUE (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 Globe Newswire 7:30 AM

-- October 21, 2026 --

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 Globe Newswire 4:05 PM

-- October 20, 2026 --

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer Globe Newswire 8:00 AM

-- October 15, 2026 --

Revolution Medicines' RASONQUE( ) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer Globe Newswire 9:45 AM

-- October 5, 2026 --

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer Globe Newswire 8:00 AM

-- September 14, 2026 --

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer Globe Newswire 4:05 PM

-- September 2, 2026 --

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer Globe Newswire 5:50 PM

-- August 26, 2026 --

Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution PRNewswire 4:34 PM

U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer Globe Newswire 12:59 PM

-- August 10, 2026 --

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration Business Wire 6:00 AM

-- August 5, 2026 --

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress Globe Newswire 4:02 PM

-- July 29, 2026 --

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 Globe Newswire 4:05 PM

-- July 22, 2026 --

Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer Globe Newswire 4:05 PM

-- July 7, 2026 --

European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process Globe Newswire 9:23 AM

-- July 2, 2026 --

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Globe Newswire 8:00 AM

-- June 24, 2026 --

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Globe Newswire 7:31 PM

-- June 23, 2026 --

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer Globe Newswire 8:00 AM

-- June 22, 2026 --

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes